Dermata Therapeutics, Inc.
DRMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $5,153 | $601 | $557 | $210 |
| - Cash | $4,664 | $6,481 | $9,719 | $3,162 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $489 | -$5,880 | -$9,163 | -$2,952 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,692 | -$1,701 | -$2,304 | -$3,151 |
| % Margin | – | – | – | – |
| Net Income | -$1,692 | -$1,701 | -$2,304 | -$3,151 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.65 | -1.66 | -4.47 | -20.4 |
| % Growth | 0.6% | 62.9% | 78.1% | – |
| Operating Cash Flow | -$1,804 | -$2,690 | -$1,934 | -$2,914 |
| Capital Expenditures | -$0 | $0 | -$0 | $0 |
| Free Cash Flow | -$1,804 | -$2,690 | -$1,934 | -$2,914 |